Costello and Franklin 2020 discuss the Zn ionophore Clioquinol treatment as a potential mechanism to deliver cytotoxic Zn levels to the ZIP-deficient malignant prostate cells and its success in controlling the androgen-independent malignant growth along with a prolactin inhibitory drug in an advanced prostate cancer patient [15]. This evidence concerns the gene PRL and prostate carcinoma.